Evidence map›Paper›PMID 40395370›Full record

ArticleFrontiers in bioinformatics2025

Tumor tissue-of-origin classification using miRNA-mRNA-lncRNA interaction networks and machine learning methods.

Ankita Lawarde, Masuma Khatun, Prakash Lingasamy, Andres Salumets, Vijayachitra Modhukur

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ankita LawardeDepartment of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Masuma KhatunDepartment of Obstetrics and Gynecology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.
Prakash LingasamyDepartment of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Andres Salumets *Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Vijayachitra Modhukur *Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: MicroRNAs (miRNAs) regulate gene expression and play an important role in carcinogenesis through complex interactions with messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs). Despite their established influence on tumor progression and therapeutic resistance, the application of miRNA interaction networks for tumor tissue-of-origin (TOO) classification remains underexplored. Methods: We developed a machine learning (ML) framework that integrates miRNA-mRNA-lncRNA interaction networks to classify tumors by their tissue of origin. Using transcriptomic profiles from 14 cancer types in The Cancer Genome Atlas (TCGA), we constructed co-expression networks and applied multiple feature selection techniques including recursive feature elimination (RFE), random forest (RF), Boruta, and linear discriminant analysis (LDA) to identify a minimal yet informative subset of miRNA features. Ensemble ML algorithms were trained and validated with stratified five-fold cross-validation for robust performance assessment across class distributions. Results: Our models achieved an overall 99% classification accuracy, distinguishing 14 cancer types with high robustness and generalizability. A minimal set of 150 miRNAs selected via RFE resulted in optimal performance across all classifiers. Furthermore, in silico validation revealed that many of the top miRNAs, including Discussion: Our integrated framework provides a biologically grounded, interpretable, and highly accurate approach for tumor tissue-of-origin classification. The identified miRNA biomarkers demonstrate strong translational potential, supported by clinical trial overlap, drug sensitivity data, and survival analyses. This work highlights the power of combining miRNA network biology with ML to improve precision oncology diagnostics and supports future development of liquid biopsy-based cancer classification.

Indexed as

ensemble learningfeature selectionmachine learningmiRNAsnetworktumor tissue origin

Identifiers

PMID40395370
PMCPMC12088952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.